NurOwn Autologous Stem Cell Transplant- a Precision Medicine Approach Using Mesenchymal Stem Cell Neurotrophic Factors for ALS (ALS-MND 2023) - Nov 8, 2023 - Abstract #CLT-09; Pres time: Dec 7, 2023; 05:45 PM - 06:45 PM; Location: Event Halle, Messe Basel, Ground Floor; "MSC-NTF treatment was well tolerated; there were no safety concerns. 33% of MSC-NTF and 28% of placebo participants met clinical response criteria at 28 wks (odds ratio [OR] = 1.33, p = 0.45); thus, the primary endpoint was not met. A pre-specified analysis of participants with baseline ALSFRS-R 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC-NTF and 16% placebo (OR = 2.6, p = 0.29)."
Bone Marrow Transplantation • CNS Disorders • Transplantation
|
|
M. Cudkowicz1; K. Taylor2; S. Lindborg2
|